Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037682 | 0.84 | CYP2D6 (0.59) | CYP2D6CD274LTA4HCNR2MAPT | |
| SCHEMBL20037663 | 0.84 | ALDH1A1 (0.58) | LTA4HCNR2HTTALDH1A1ACHE | |
| SCHEMBL20037672 | 0.84 | ALDH1A1 (0.58) | LTA4HCNR2HTTALDH1A1ACHE | |
| SCHEMBL18291479 | 0.84 | ALDH1A1 (0.58) | LTA4HCNR2HTTALDH1A1ACHE | |
| SCHEMBL20037827 | 0.83 | HRH3 (0.48) | LTA4HACHEHRH3 | |
| SCHEMBL20249110 | 0.81 | CYP2D6 (0.55) | CYP2D6CD274LTA4HCNR2MAPT | |
| SCHEMBL20038497 | 0.78 | PDE2A (0.38) | CYP2D6CD274MAPTHTTPDE2A | |
| SCHEMBL20255702 | 0.78 | ALDH1A1 (0.47) | CYP2D6CD274LTA4HALDH1A1 | |
| SCHEMBL20255353 | 0.78 | ALDH1A1 (0.47) | CYP2D6CD274LTA4HALDH1A1 | |
| SCHEMBL6267504 | 0.77 | CYP2D6 (0.72) | CYP2D6LTA4HMAPTHTTPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CYP2D6 70/4885CD274 1164/4885LTA4H 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.